Pharmacy Quality Initiatives
Vaccinations
HPV vaccine in pre-teens/teens is essential.
The American Academy of Pediatrics (AAP) recommends routine HPV vaccination for females and males. The AAP recommends starting the series between 9 and 12 years, at an age that the provider deems optimal for acceptance and completion of the vaccination series.
HPV vaccine has an outstanding safety profile
It is our responsibility as health providers to ensure that our families have the information they seek regarding this vaccine and its safety profile.
It is reported in “Trends in Reasons for Human Papillomavirus Vaccine Hesitancy: 2010-2020,” (Adjei Boakye E, et al. Pediatrics. May 23, 2023) that parents express more hesitancy now related to concerns for safety than previously.
Many experts attribute this increased hesitancy to social media anti-vaccine campaigns.
We know that amid all the current health mandates providers have much to discuss with families, but please be sure that you support and remind parents of the need for both the initial vaccine and the booster 5 months after the initial vaccine.
Buckeye Health Plan is partnering with you in this effort and we stand ready to remind families of this medical need and support you as you educate your patients regarding the HPV vaccine.
Medication Adherence
We all recognize the critical role medication adherence plays in managing chronic disease. In fact, research continues to show that how consistently a patient takes their medication often has a greater impact on health outcomes than the specific treatment itself. For patients living with chronic conditions, adherence is not simply about following instructions—it is foundational to improving health, preventing complications, and enhancing quality of life.
Starting the conversation early and often about taking medications as prescribed sets patients up for success throughout the year. These discussions help normalize challenges, surface barriers, and create opportunities for meaningful intervention—benefiting both patients and care teams.
Why Medication Adherence Still Matters—Now More Than Ever
Despite advances in treatment options, pharmacy benefits, and care models, medication non‑adherence remains a widespread issue.
- National and international health organizations continue to report that over half of medications prescribed for chronic diseases are not taken as directed, a trend that has remained remarkably persistent over time. [heart.org]
- Poor medication adherence is strongly associated with higher hospitalization rates, worse disease control, increased morbidity and mortality, and avoidable healthcare spending. [adheretech.com]
- In the United States alone, medication non‑adherence is estimated to contribute $100–$300 billion annually in avoidable medical costs, driven by emergency department visits, hospital admissions, and disease progression. [heart.org], [adheretech.com]
Early studies show a measurable reduction in patients skipping or delaying medications due to cost, particularly among those with multiple chronic conditions. Even so, financial pressure, forgetfulness, side effects, and health literacy challenges continue to be major drivers of missed doses across all populations. [jamanetwork.com], [news.harvard.edu]
The Most Important Step: Listening to the Patient
When it comes to improving medication adherence, the most effective intervention is often the simplest: listen first.
Understanding why a patient is struggling allows care teams to tailor solutions that are realistic and sustainable. Non‑adherence is rarely intentional. Instead, it is typically the result of competing priorities, misunderstanding, or system‑level barriers.
Common themes continue to emerge across studies and care settings:
- Forgetfulness or difficulty managing complex regimens.
- Financial concerns or cost‑sharing.
- Side effects or fear of adverse reactions
- Limited understanding of the medication’s purpose or benefit
- Belief that the medication is no longer needed once symptoms improve.
By creating space for open dialogue, providers can identify these barriers early and address multiple gaps in care simultaneously.
Practical Strategies That Make a Real Difference
Once barriers are identified, minor changes can lead to meaningful improvements in adherence and outcomes.
One proven approach is simplifying medication regimens whenever possible. This may include:
- Transitioning stable chronic medications to extended‑day supplies (especially 100-day supplies), which has been consistently associated with higher adherence rates and fewer refill gaps.
- Reducing dosing frequency
- Aligning refill schedules across medications
Education also plays a critical role. Patients are more likely to remain adherent when they understand:
- What is the medication treating?
- What side effects to expect—and which ones warrant a call?
- How does the medication fit into their long‑term health goals?
Written instructions, plain‑language counseling, and the use of health‑literacy‑appropriate tools can reinforce these conversations and improve retention.
Leveraging Data and Tools to Focus Efforts Where They Matter Most
In today’s environment, data‑driven tools allow care teams to work smarter—not harder.
Solutions like RxEffect, EQUIPP, or OutcomesMTM help identify patients at the highest risk for non‑adherence, enabling more targeted and meaningful conversations. By prioritizing patients with multiple barriers or declining adherence patterns, providers can address medication challenges proactively rather than reactively. This focused approach supports both quality performance goals and patient‑centered care, allowing multiple care gaps to be addressed in a single interaction.
Simple Tips to Support Better Adherence
Listen
- Ask open‑ended questions: Are they taking their medications? If not, why?
- Normalize missed doses to encourage honest conversation.
Understand
- Explore how often doses are missed and what gets in the way.
- Assess financial, cognitive, and logistical barriers.
Act
- Educate on side effects and expectations.
- Provide clear, written instructions.
- Brainstorm solutions for scheduling or routine challenges.
- Connect patients to financial assistance or support programs.
- Simplify regimens when clinically appropriate.
Medication adherence remains one of the most powerful—and modifiable—drivers of health outcomes. By listening closely, simplifying where possible, and leveraging the right tools, we can help patients stay on track, improve quality of life, and reduce avoidable utilization. As always, our team is here to support you in this work.
Asthma
Asthma Controller Medication (ACM) is an Outcomes Acceleration for Kids (OAK) measure that identifies patients with persistent asthma and whether these patients receive ongoing controller therapy.
Did you know?
- In 2023, current asthma rates in Ohio were 159,955 (6.8%) in children.¹
- In 2018, 2.2 million children aged 5-17 years missed more than 7.9 million school days due to asthma. 1
- Up to 80% of patients cannot use their inhaler correctly!
- GINA (Global Initiative for Asthma) does not recommend treatment of asthma in adults, adolescents, or children 6-11 years with short-acting beta2 agonist (SABA) alone. Instead, they should receive inhaled corticosteroid (ICS)-containing treatment to reduce their risk of severe exacerbations and to control symptoms.²
Currently Buckeye Health Plan (BHP) has in place the following initiatives specific to the pediatric population with asthma:
- In conjunction with our data analytics team, a daily report is generated that identifies BHP members who are non-adherent to their asthma controller medications as well as those filling multiple rescue inhalers.
- Our pharmacy team makes fax attempts as well as phone outreaches to providers, including topics such as non-adherence to controller medications, extended day supplies, those with no controller medications, and multiple rescue inhaler fills.
- In addition, our pharmacy team also sends out educational text messages to our asthma members regarding topics such as asthma triggers, smoking cessation, children having inhalers at school, SMART, and vaccinations.
Please consider the following:
- Assess asthma severity at every visit and the need for controller therapy. Persistent asthma should always prompt controller therapy.
- Ensure an asthma assessment is completed at least yearly.
- During each visit with the member, review their medication list and ask if there are any issues with filling or taking medications as prescribed.
- Provide an asthma action plan if the member does not already have one.
- Discuss with members the difference between their rescue inhalers and controller inhalers/medications and make sure they understand how and when to use each.
- Consider prescribing a spacer with a mask to ensure the member is using their inhaler correctly and getting the full dose.
- Address medication therapy if a member is overutilizing their rescue inhaler.
- Determine if SMART (Single Maintenance and Reliever Therapy) may be appropriate for a member.
- Offer an extended day supply of medications (up to a 100 day supply) to help improve adherence and lessen member trips to the pharmacy.
- Continue to monitor a member’s progress and follow up as needed.
References:
1. American Lung Association. (2026). Asthma Trends and Burden.
2. Global Initiative For Asthma (GINA). (2026).
Be SMART with Asthma
SMART stands for Single Maintenance and Reliever Therapy and is currently recommended in patients 4 years of age and older with moderate to severe asthma. This type of asthma treatment involves the use of one inhaler that includes an inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA), specifically formoterol, for both maintenance and reliever therapy.
ICS-LABA (formoterol) Combinations on the Market | Notes |
Symbicort®™ (budesonide/formoterol) | Preferred for SMART; extensively studied |
Dulera®™ (mometasone/formoterol) | Can be used for SMART; not currently studied |
According to the Asthma Management Guidelines updated in 2020 by the National Heart, Lung, and Blood Institute (NHLBI), patients on daily ICS-LABA treatment plus as needed short-acting beta agonist (SABA) that are uncontrolled may benefit from SMART. Evidence supports switching to SMART at the same or lower maintenance ICS-LABA dose before considering a step up in maintenance treatment. If patients are well controlled on the ICS-LABA plus SABA treatment, SMART may offer less added benefit; thus, the regimen should be maintained. Additionally, the Global Initiative for Asthma (GINA) guidelines were updated in May of 2024 to clarify and continue support for SMART for moderate to severe asthma from its initial inclusion in the December 2022 update of the GINA guidelines.
Clinical Trial | Medications Studied | Test Population | Key Results | Clinical Takeaways |
SYGMA 1 & 2 | As-needed budesonide/formoterol vs daily budesonide + SABA or SABA alone | Adults with mild asthma | 26–66% reduction in severe exacerbations vs comparators | Supports replacing SABA-only therapy with ICS/formoterol |
Novel START | As-needed budesonide/formoterol vs albuterol or daily budesonide | Adults with mild asthma | 60% reduction in severe exacerbations vs albuterol | Anti-inflammatory reliever superior to albuterol alone |
Patel et al., 2013 | Budesonide/formoterol as maintenance + reliever (SMART) | Adults with recent exacerbations | Fewer severe exacerbations, less oral steroid use | One inhaler strategy reduces exacerbation risk |
Beasley et al., 2014 | SMART vs fixed-dose ICS/LABA + SABA | Adults at high exacerbation risk | ~50% fewer severe exacerbations | SMART preferred over stepping up dose |
Bateman et al., 2018 (SYGMA 2) | As-needed budesonide/formoterol vs daily budesonide | Patients ≥12 years with mild asthma | Similar control with lower steroid exposure | Supports Step 2 SMART approach |
Pediatric SMART Trials | Budesonide/formoterol | Children ≥4 years | Consistent exacerbation reduction | Supports pediatric SMART at GINA Step 3 |
Based on the current evidence and continued studies, the decrease in medication burden and reduction in medication costs for patients with asthma by utilizing SMART is clinically significant. Here are some important points for all clinicians to keep in mind:
- Traditional asthma management uses different medications for maintenance and reliever therapy whereas SMART uses the same medication for BOTH!
- SMART may reduce the risk of confusion on which inhaler to use for maintenance or reliever for many patients, especially children.
- SMART is part of the National Asthma Education and Prevention Program (NAEPP) and is detailed in the 2020 NHLBI and 2024 GINA guidelines.
- If symptoms are well controlled with two inhalers, it is appropriate to maintain that regimen; but SMART is recommended for patients with moderate to severe persistent asthma aged 4 years and older.
- SMART medications are FDA approved in patients 12 years or older and guidelines recommend off-label use of SMART in children aged 4 to 11 years.
Key Resources and References
- Bateman ED et al. N Engl J Med.
2018;378:1877–1887. (SYGMA 1) - O’Byrne PM et al. N Engl J Med.
2018;378:1865–1876. (SYGMA 2) - Beasley R et al. N Engl J Med.
2019;380:2020–2030. (Novel START) - Patel M et al. Lancet Respir Med. 2013;1:32–42.
- Beasley R et al. Eur Respir J. 2014;44:134–143.
- Beasley R et al. JAMA Netw Open. 2022;5:e222365.
- Global Initiative for Asthma (GINA). Global
Strategy for Asthma Management and Prevention, 2024.
AMR: Asthma Medication Ratio
Asthma Medication Ratio (AMR) is a HEDIS measure that focuses on patients with persistent asthma and looks at the number of their controller medication fills in relation to total asthma medication fills (rescue and controller).
Did you know?
- In 2023, current asthma rates in Ohio were 159,955 (6.8%) in children and 1,007,049 (11.0 %) in adults. ¹
- Up to 80% of patients cannot use their inhaler correctly!
- At least 50% of adults and children do NOT take controller medications as prescribed.
- Regular use of SABA (short acting beta agonist), even for 1-2 weeks, is associated with increased AHR (airway hyperresponsiveness), reduced bronchodilator effect, increased allergic response, and increased eosinophils. This can lead to a vicious cycle encouraging overuse. Overuse of SABA is associated with increased exacerbations and increased mortality. ²
- GINA (Global Initiative for Asthma) does not recommend treatment of asthma in adults, adolescents, or children 6-11 years with short-acting beta2 agonist (SABA) alone. Instead, they should receive inhaled corticosteroid (ICS)-containing treatment to reduce their risk of severe exacerbations and to control symptoms.²
Currently Buckeye Health Plan (BHP) has in place the following initiatives:
- In conjunction with our data analytics team, a daily report is generated that identifies BHP members who are non-adherent to their asthma controller medications as well as those filling multiple rescue inhalers.
- Our pharmacy team makes fax attempts as well as phone outreaches to providers, including topics such as non-adherence to controller medications, extended day supplies, those with no controller medications, and multiple rescue inhaler fills.
- Our pharmacy team also sends out text messages to members who are non-adherent to their asthma controller medications, reminding them that their medication is important in controlling their asthma.
- In addition, our pharmacy team also sends out educational text messages to our asthma members regarding topics such as asthma triggers, smoking cessation, children having inhalers at school, SMART, and vaccinations.
Please consider the following:
- During each visit with the member, review their medication list and ask if there are any issues with filling or taking medications as prescribed.
- Provide an asthma action plan if the member does not already have one.
- Discuss with members the difference between their rescue inhalers and controller inhalers/medications and make sure they understand how and when to use each.
- Consider prescribing a spacer with a mask to ensure the member is using their inhaler correctly and getting the full dose.
- Address medication therapy if a member is overutilizing their rescue inhaler.
- Determine if SMART (Single Maintenance and Reliever Therapy) may be appropriate for a member.
- Offer an extended day supply of medications to help improve adherence and lessen member trips to the pharmacy.
- Continue to monitor a member’s progress and follow up as needed.
References:
Opioid
Provider Quality Update | Medicaid
The Use of Opioids From Multiple Providers (UOP) measure identifies adult members receiving opioid prescriptions from multiple prescribers and/or pharmacies. Fragmented opioid care can increase the risk of medication interactions, overdose, hospitalization and other adverse outcomes. The measure reports members receiving opioids from four or more prescribers, four or more pharmacies, or both. Members receiving hospice services are excluded.
Why it matters
A 2023 systematic review of 28 studies involving nearly 24 million patients identified multiple opioid prescribers and pharmacies among the strongest predictors of fatal and nonfatal overdose, with associated risks approximately two- to six-fold higher. NCQA also reports that Medicare beneficiaries receiving opioids from four prescribers had an adjusted overdose risk of 6.4 per 1,000 beneficiary-years, while use of five pharmacies was associated with an adjusted risk of 12.87 per 1,000 beneficiary-years.
How providers can help
- Review Ohio’s Automated Rx Reporting System (OARRS) before prescribing controlled substances and when clinically appropriate during ongoing opioid therapy.
- Ask members about all opioid prescriptions and dispensing locations, including care received from specialists, urgent care centers or emergency departments.
- Encourage members to use one pharmacy whenever feasible to support medication oversight and reduce duplication.
- Coordinate with other prescribers and pharmacists so the care team shares the same pain-management plan.
- Follow up after opioid initiation or significant therapy changes to reassess pain, safety and treatment goals.
Conversation tip
“To help keep your medications safe and coordinated, are there any other providers prescribing pain medications or pharmacies you have used recently?” |
Additional support
For members who may benefit from additional oversight and care coordination, providers may request an evaluation for the Buckeye Pharmacy Lock-In Coordinated Services Program. By partnering with members, pharmacists, behavioral health providers, specialists and primary care providers, we can help reduce fragmented opioid prescribing and promote safer, more coordinated care.
References: 1. Wang L, et al. Predictors of fatal and nonfatal overdose after prescription of opioids for chronic pain: a systematic review and meta-analysis of observational studies. CMAJ. 2023;195:E1399-E1411. doi:10.1503/cmaj.230459. 2. NCQA. Use of Opioids From Multiple Providers (UOP). Accessed August 20, 2026. 3. State of Ohio Board of Pharmacy. Ohio Automated Rx Reporting System (OARRS).
The Concurrent Use of Opioid and Benzodiazepine (COB) measure, which is part of the 2026 Medicare Star Ratings program, focuses on the use of concurrent prescription opioid and benzodiazepine medications in adults, aged 18 and older. While there are instances where it is appropriate for concurrent use of these medications, the use of prescription opioids and benzodiazepines together is deemed a serious safety concern for most members.
- Nationally, in 2021 nearly 1 in 7 overdose deaths involving opioids also involved benzodiazepines [i]
- In Ohio, from 2022 to 2023 there were increases in the number of unintentional drug overdose deaths involving the non-opioid drug categories of cocaine and benzodiazepines. The number of drug overdose deaths involving cocaine increased 7%, and deaths involving benzodiazepines increased 4% [ii]
- Ohio surveillance data show that benzodiazepines are increasingly involved in overdose deaths and frequently co‑occur with opioids, contributing to fatal and nonfatal respiratory‑depressant toxicity, despite overall declines in overdose deaths statewide
- Key points for this measure include:
• Members qualify for the measure with at least 15 days supply of an opioid (with at
least 2 unique fills on different dates of service)
• Members are non-compliant by having at least 30 days of overlap with any
benzodiazepine (at least 2 unique benzodiazepine fills on different dates of service
are required)
• Once a member surpasses 30 days of overlap they can no longer become
compliant during the measurement year
• Exclusions include any member with a diagnosis of cancer, sickle-cell disease or
hospice enrollment
We recommend a review of these medications for medical necessity and discontinuation of one or both, if clinically appropriate. If concurrent use is unavoidable, we recommend continuing at the lowest effective doses along with the shortest duration possible. Other considerations when your patient is taking these medications together include:
• Monitor patients closely for signs of misuse or adverse effects
• For discontinuation of one or both medications avoid doing so abruptly unless
patient safety requires doing so. Instead, use a slow taper to help avoid withdrawal
symptoms
• Educating your patient about the risks of combining these medications which may
include increased risk of falls and fractures, excessive sedation and respiratory
depression
• Checking Prescription Drug Monitoring Programs (PDMPs) to track controlled
substance use
[i] National Institute on Drug Abuse, “Benzodiazepines and Opioids,” November 7, 2022
[ii] Ohio Department of Health, “Ohio Unintentional Drug Overdose Report,” accessed March 13, 2026
Our Mission
Mission: This task force will be responsible for establishing the evidence based multi-disciplinary interventions that Buckeye Health Plan will engage in to combat the opioid epidemic in Ohio.
Desired Outcomes
- Reduce residential treatment 30-day readmissions. Target: decrease the residential treatment 30-day readmission rate from 22.3% to 20.3% by 12/31/2027.
- Improve timely follow-up after an emergency department visit for substance use disorder. Target: meet or exceed the 75th percentile for FUA 7-day (32.86%) and FUA 30-day (45.66%) by 12/31/2026.
- Shape the substance use disorder provider network using quality outcomes. Goal: contract with high-quality providers, measured by performance at or above the 75th percentile for IET, HDO, UOP, COU, and POD by MY2028.
- Increase medication-assisted therapy (MAT) treatment for members with opioid use disorder. Target: increase the percentage of members with OUD being treated with MAT by 5% from 7/1/26 to 7/1/28.
- Reduce unintentional opioid-related overdoses by 10% by 12/31/2027.
As part of the initiative to combat the opioid epidemic, Buckeye Health Plan has adopted a Drug Management Program (DMP) for beneficiaries at-risk for misuse or abuse of frequently abused medications.
Background:
Section 704 of the Comprehensive Addiction and Recovery Act (CARA) of 2016 included provisions permitting Part D sponsors to establish Drug Management Programs (DMPs) for beneficiaries at-risk for misuse or abuse of frequently abused drugs (FADs).
CMS published a final rule (CMS-4182-F) on April 16, 2018 (“final rule”) that established the framework under which Part D plan sponsors may establish a DMP. This rule codified the many aspects of the retrospective Part D Opioid Drug Utilization Review (DUR) Policy and Overutilization Monitoring System (OMS), with adjustments as needed to comply with CARA, by integrating them into the DMP provisions at 42 CFR § 423.153(f).
Starting in January 2019, sponsors that adopted a DMP must engage in the case management of each Potential At-Risk Beneficiary (PARB) reported through OMS and provide information related to their review within 30 days. In addition, sponsors must also report through OMS any sponsor-identified PARBs, and any newly enrolled PARBs or At-Risk Beneficiaries (ARBs) for which a sponsor received a transaction reply code (TRC) of ‘376’ (New Enrollee CARA Status Notification) from the daily transaction reply report (DTRR).
See additional DMP guidance on the CMS Part D Overutilization website.
CMS policies also include drug management programs to encourage care coordination and safe use of opioids as required by the Comprehensive Addiction and Recovery Act of 2016. Starting in 2019, for patients who could potentially abuse or misuse prescription drugs - including opioids and benzodiazepines - a Medicare drug plan will contact prescribers through case management to review patients’ total utilization pattern of frequently abused drugs and discuss the following :
1. Use of opioids with an average daily morphine milligram equivalent (MME) equal to or exceeding 90 mg for any duration during the most recent 6 months and either: 3 or more opioid prescribers and 3 or more opioid dispensing pharmacies OR 5 or more opioid prescribers, regardless of the number of opioid dispensing pharmacies. These cases are identified through OMS or by sponsors.
2. Use of opioids (regardless of average daily MME) during the most recent 6 months with 7 or more opioid prescribers OR 7 or more opioid dispensing pharmacies. These cases are identified by sponsors.
The Concurrent Use of Opioid and Benzodiazepine (COB) measure, which is part of the 2025 Medicare Star Ratings program, focuses on the use of concurrent prescription opioid and benzodiazepine medications in adults, aged 18 and older. While there are instances where it is appropriate for concurrent use of these medications, the concurrent use of prescription opioids and benzodiazepines is deemed a serious safety concern for most members. For a member to be eligible they must have:
- At least two prescription claims for opioid medications with different dates of service totaling at least 15 cumulative days supply of opioids
AND - At least two prescription claims for any benzodiazepine with different dates of service with concurrent use of opioids and benzodiazepines for at least 30 cumulative days
We recommend a review of these medications and discontinuation of one or both, if possible. If concurrent use is unavoidable, we recommend continuing at the lowest effective doses along with the shortest duration possible. Other considerations when your patient is taking these medications together include:
- Monitor patients closely for signs of misuse or adverse effects
- For discontinuation of one or both medications avoid doing so abruptly unless patient safety requires doing so. Instead, use a slow taper to help avoid withdrawal symptoms.
- Educating your patient about the risks of combining these medications which may include increased risk of falls and fractures, excessive sedation and respiratory depression
- Checking Prescription Drug Monitoring Programs (PDMPs) to track controlled substance use
Statins
Patients with diabetes remain at substantially increased risk for atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, ischemic stroke, and cardiovascular death. Statin therapy is one of the most effective interventions available to reduce that risk, but its benefit depends on identifying eligible patients, selecting an appropriate regimen, and helping patients remain on treatment.
Diabetes and Cardiovascular Disease Remain a Major Health Burden
According to the CDC National Diabetes Statistics Report, an estimated 40.1 million Americans, or 12.0% of the U.S. population, had diabetes in 2023, including approximately 11.0 million individuals who remain undiagnosed. In addition, an estimated 115.2 million U.S. adults have prediabetes.
The American Diabetes Association Standards of Care in Diabetes—2026 identify ASCVD as the leading cause of morbidity and mortality among people with diabetes and note that diabetes independently increases ASCVD risk.
These statistics highlight an important clinical reality: diabetes is not only a glycemic condition, it is also a major cardiovascular risk condition. Cardiovascular prevention should remain a long-term priority throughout the continuum of diabetes care.
Why Statins Matter Clinically
For patients with diabetes, statins are more than medications used to improve a cholesterol laboratory value. Appropriate LDL-C lowering reduces the likelihood of major cardiovascular events, including myocardial infarction, ischemic stroke, and coronary revascularization. For many patients with diabetes, cardiovascular disease develops silently for years before the first clinical event occurs. A brief medication review, adherence discussion, or statin-intolerance assessment during a routine visit may preserve a therapy capable of substantially reducing future cardiovascular events.
Appropriate statin therapy helps reduce cardiovascular risk through LDL-C reduction, plaque stabilization, and reduction of vascular inflammation. Across large statin trials, each approximately 39 mg/dL reduction in LDL-C has been associated with about a 22% relative reduction in major vascular events.
Statin intensity and the need for additional lipid-lowering therapy should be individualized based on age, ASCVD history, overall cardiovascular risk, LDL-C response, comorbidities, pregnancy status and pregnancy planning, drug interactions, and tolerability.
The 2026 ACC/AHA multisociety dyslipidemia guideline also emphasizes risk-based LDL-C and non-HDL-C treatment goals, use of the PREVENT-ASCVD equations for primary-prevention risk assessment, and measurement of lipoprotein(a) at least once in adulthood.
By combining appropriate statin therapy, patient-centered education, shared decision-making, and pharmacy collaboration, care teams can help patients receive the full cardiovascular benefit of long-term lipid-lowering treatment.
Reducing Future Cardiovascular Events
The 2026 Heart Disease and Stroke Statistics Update reported that cardiovascular disease accounted for 915,973 U.S. deaths in 2023, and approximately 130.6 million U.S. adults (48.9%) had some form of cardiovascular disease, including hypertension, during 2021–2023. Current CDC data indicate that approximately 805,000 Americans experience a heart attack each year.
Because diabetes significantly increases cardiovascular risk, statin therapy represents an important opportunity to reduce the likelihood of future cardiovascular events before ASCVD develops or progresses. Along with blood pressure management, smoking cessation, weight management, and glucose control, appropriate statin therapy remains a cornerstone of comprehensive cardiovascular risk reduction.
Medication Adherence Is Essential to Realizing the Benefit
Prescribing a statin is only the first step. Patients must continue treatment to receive its long-term cardiovascular benefits.
Common barriers include:
- Concern about adverse effects
- Difficulty understanding the preventive purpose of therapy
- Medication cost or access problems
- Competing health priorities
- Complex medication regimens
- Refill gaps or missed follow-up appointments
A focused medication discussion can uncover barriers before they lead to discontinuation. Providers may consider asking:
- “Are you currently taking your statin?”
- “How many doses do you miss during a typical week?”
- “Have you experienced any symptoms or concerns since starting it?”
- “What might make it easier for you to take this medication consistently?”
Framing the discussion around preventing heart attacks and strokes may be more meaningful to patients than focusing only on LDL-C values.
Managing Possible Statin Intolerance
Muscle symptoms may occur during statin treatment, but the American College of Cardiology Statin Intolerance Tool notes that true statin intolerance is uncommon. The tool recommends obtaining a thorough symptom history and using statin discontinuation and rechallenge when appropriate to identify a tolerable statin and dose.
When a patient reports possible adverse effects, consider:
- Reviewing the timing, location, and severity of symptoms
- Evaluating potential drug interactions and other contributing conditions
- Temporarily holding therapy when clinically appropriate to assess symptom resolution
- Rechallenging with the same statin at a lower dose
- Switching to a different statin
- Considering an alternative dosing schedule when appropriate
- Using the maximally tolerated statin dose, even if it is less than the originally intended intensity
- Considering additional lipid-lowering therapy when LDL-C lowering remains inadequate or a patient cannot tolerate an effective statin regimen
Statin intolerance may be partial or complete, and symptoms may not always be directly caused by the medication. Maintaining some tolerated statin exposure may be preferable to complete discontinuation for a patient at elevated cardiovascular risk.
Shared Decision-Making Can Improve Persistence
Patients are more likely to remain engaged when they understand their cardiovascular risk, the expected benefit of treatment, and the options available if adverse effects occur.
Effective shared decision-making may include:
- Connecting statin therapy to cardiovascular risk reduction.
- Explaining expected benefit in understandable terms.
- Asking about the patient’s goals and concerns.
- Discussing treatment alternatives if the initial regimen is not tolerated.
- Agreeing on a monitoring and follow-up plan.
- Reinforcing that treatment decisions can be revisited rather than stopping therapy without an alternative plan.
How Pharmacy and Prescribers Can Work Together
Pharmacists can partner with prescribers to identify medication gaps, optimize statin therapy, and help patients remain on treatment. Pharmacists can support the statin space by:
- Identifying patients with diabetes who do not have a current statin prescription or fill and notifying the prescriber of the potential care gap
- Reviewing the medication list, refill history, and adherence patterns to identify opportunities for initiation or optimization
- Educating patients about how statins reduce the risk of heart attack or stroke and addressing questions or misconceptions
- Contacting patients with refill gaps, helping synchronize medications, arranging refill reminders, and supporting extended-day supplies, such as 100-day supplies, when clinically appropriate and covered
- Exploring affordability, transportation, prior authorization, formulary, and other medication-access barriers
- Assessing reported muscle symptoms, timing, severity, potential interactions, and other contributing factors before therapy is discontinued
- Recommending prescriber review of a lower dose, different statin, alternative dosing schedule, or maximally tolerated regimen when clinically appropriate
- Reinforcing follow-up and clinically indicated laboratory monitoring; routine CK or repeated liver-enzyme monitoring is not required for every asymptomatic patient. Baseline liver-enzyme testing and symptom-directed CK or liver-enzyme testing should be performed when clinically indicated.
- Sharing specific, actionable recommendations with the prescriber and documenting the agreed-upon follow-up plan
Health plan gap reports can further support this collaboration by identifying patients who may not be receiving statin therapy or whose prescription claims suggest possible discontinuation. Claims information should prompt medication reconciliation and patient outreach rather than be treated as definitive evidence that a patient is not taking therapy.
Practical Prescribing Pearls
- Focus on cardiovascular protection. Explain that the purpose of statin therapy is to reduce the risk of future heart attacks and strokes.
- Incorporate statin discussions into routine diabetes visits.
- Do not assume a prescription equals adherence. Review refill history and ask directly about missed doses.
- Investigate symptoms before labeling a patient statin intolerant.
- Rechallenge when clinically appropriate. A different statin, lower dose, or alternative schedule may be tolerated.
- Use maximally tolerated therapy whenever possible.
- Consider cardiovascular risk reduction alongside glycemic control during routine diabetes management.
- Engage pharmacy early. Pharmacists can assist with adherence, education, access barriers, potential interactions, and follow-up.
The Opportunity During Every Visit
For many patients with diabetes, cardiovascular disease develops silently for years before the first clinical event occurs. A brief medication review, adherence discussion, or statin-intolerance assessment during a routine visit may preserve a therapy capable of substantially reducing future cardiovascular events.
By combining appropriate statin therapy, patient-centered education, shared decision-making, and pharmacy collaboration, care teams can help patients receive the full cardiovascular benefit of long-term lipid-lowering treatment.
References
- National Diabetes Statistics Report. Centers for Disease Control and Prevention. Updated September 16, 2026; accessed October 2026. An estimated 40.1 million Americans (12.0% of the U.S. population) had diabetes in 2023, including approximately 11.0 million people with undiagnosed diabetes. CDC National Diabetes Statistics Report
- A U.S. Report Card: Diabetes in the United States. Centers for Disease Control and Prevention. Updated February 11, 2026; accessed October 2026. An estimated 115.2 million U.S. adults have prediabetes, and more than one in four adults with diabetes are unaware they have the condition. CDC Diabetes Report Card
- Standards of Care in Diabetes—2026: Cardiovascular Disease and Risk Management. American Diabetes Association. ASCVD remains the leading cause of morbidity and mortality among people with diabetes, and diabetes independently increases ASCVD risk. ADA Standards of Care—2026
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Updated March 13, 2026. The guideline replaces the 2018 cholesterol guideline and provides updated recommendations on risk assessment, LDL-C and non-HDL-C treatment goals, statin intolerance, nonstatin therapy, and lipoprotein(a) testing. 2026 Dyslipidemia Guideline.
- 2026 Heart Disease and Stroke Statistics Update Fact Sheet At-a-Glance. American Heart Association. Cardiovascular disease accounted for 915,973 U.S. deaths in 2023 and affected approximately 130.6 million U.S. adults, including people with hypertension. AHA 2026 Statistics Fact Sheet
- Heart Disease Facts. Centers for Disease Control and Prevention. Approximately 805,000 Americans experience a heart attack annually. CDC Heart Disease Facts
- Statin Therapy Versus Control. Cholesterol Treatment Trialists’ Collaboration. Each 1 mmol/L (39 mg/dL) reduction in LDL-C is associated with approximately 22% fewer major vascular events and 10% lower all-cause mortality. CTT Statin Efficacy Findings
- Efficacy and Safety of More Intensive Lowering of LDL Cholesterol. Cholesterol Treatment Trialists’ Collaboration. More intensive LDL-C lowering provides additional reductions in major cardiovascular events. The Lancet meta-analysis
- Statin Intolerance Tool. American College of Cardiology. Guidance for evaluating and managing possible statin intolerance. ACC Statin Intolerance Tool
- NLA 2022 Definition of Statin Intolerance. American College of Cardiology expert analysis. Statin intolerance may be partial or complete, and evaluation should account for modifiable contributors and the patient’s ability to tolerate an alternative statin regimen. ACC expert analysis
Patients with established atherosclerotic cardiovascular disease (ASCVD) remain at substantial risk for recurrent myocardial infarction, ischemic stroke, and cardiovascular death. Statin therapy is one of the most effective interventions available to reduce that risk, but its benefit depends on selecting an appropriate regimen and helping patients remain on treatment.
Cardiovascular Disease Remains a Major Health Burden
The 2026 Heart Disease and Stroke Statistics Update from the American Heart Association reported that cardiovascular disease was the underlying cause of 915,973 deaths in the United States in 2023. Approximately 130.6 million U.S. adults, or 48.9%, had some form of cardiovascular disease between 2021 and 2023.
Current CDC Heart Disease Facts report that someone in the United States has a heart attack approximately every 40 seconds. Of the estimated 805,000 heart attacks that occur each year, approximately 200,000 occur in people who have already experienced a heart attack.
These statistics highlight an important clinical reality: surviving an initial cardiovascular event does not eliminate risk. Secondary prevention must remain a long-term priority.
Why Statins Matter Clinically
Patients with ASCVD remain at risk even when they feel well and their cardiovascular event occurred years ago. A brief medication review, adherence discussion, or statin-intolerance assessment during a routine visit may preserve a therapy capable of substantially reducing future cardiovascular events. For patients with ASCVD, statins are more than medications used to improve a cholesterol laboratory value. Appropriate LDL-C lowering reduces the likelihood of major vascular events, including myocardial infarction, ischemic stroke, and coronary revascularization.
High-Intensity Statins: A Foundation of Secondary Prevention
The 2026 ACC/AHA multisociety guideline identifies statins as the foundation of lipid-lowering therapy for patients with clinical ASCVD. High-intensity statin therapy should be used when clinically appropriate and tolerated, with treatment individualized through clinician-patient discussion. The guideline again uses LDL-C and non–HDL-C treatment goals while continuing to emphasize the percentage reduction achieved from baseline.
Common high-intensity statin regimens include:
- Atorvastatin 40–80 mg daily
- Rosuvastatin 20–40 mg daily
When high-intensity therapy is not tolerated, a maximally tolerated statin regimen may still provide meaningful cardiovascular protection. For patients with clinical ASCVD, LDL-C goals and the need for additional therapy should be individualized according to recurrent-event risk. Patients at very high risk generally have an LDL-C goal of <55 mg/dL. If the applicable LDL-C goal is not achieved on maximally tolerated statin therapy, add-on non-statin therapy should be considered through clinician-patient discussion. The goal is to maintain effective lipid-lowering therapy rather than abandon treatment after a single unsuccessful trial.
Medication Adherence Is Essential to Realizing the Benefit
Prescribing a statin is only the first step. Patients must continue treatment to receive its long-term cardiovascular benefits.
Common barriers include:
- Concern about adverse effects
- Difficulty understanding the preventive purpose of therapy
- Medication cost or access problems
- Competing health priorities
- Complex medication regimens
- Refill gaps or missed follow-up appointments
A focused medication discussion can uncover barriers before they lead to discontinuation. Providers may consider asking:
- “Are you currently taking your statin?”
- “How many doses do you miss during a typical week?”
- “Have you experienced any symptoms or concerns since starting it?”
- “What might make it easier for you to take this medication consistently?”
Framing the discussion around preventing another heart attack or stroke may be more meaningful to patients than focusing only on LDL-C values.
Managing Possible Statin Intolerance
Muscle symptoms may occur during statin treatment, but true statin intolerance is uncommon. It is recommended to obtain a thorough symptom history and use statin discontinuation and rechallenge when appropriate to identify a tolerable statin and dose.
When a patient reports possible adverse effects, consider:
- Reviewing the timing, location, and severity of symptoms
- Evaluating potential drug interactions and other contributing conditions
- Temporarily holding therapy when clinically appropriate to assess symptom resolution; severe muscle symptoms, marked weakness, dark or discolored urine, fever, or suspected rhabdomyolysis require prompt clinical evaluation rather than routine outpatient rechallenge
- Rechallenging with the same statin at a lower dose
- Switching to a different statin
- Considering an individualized intermittent or alternative dosing schedule for selected patients when daily dosing is not tolerated, while recognizing that this is not equivalent to a standard daily high-intensity regimen
- Using the maximally tolerated statin dose, even if it is less than the originally intended intensity
- Considering additional lipid-lowering therapy when LDL-C lowering remains inadequate or a patient cannot tolerate an effective statin regimen
Statin intolerance may be partial or complete, and symptoms may not always be directly caused by the medication. Maintaining some tolerated statin exposure may be preferable to complete discontinuation for a patient at high cardiovascular risk.
Shared Decision-Making Can Improve Persistence
Patients are more likely to remain engaged when they understand their personal cardiovascular risk, the expected benefit of treatment, and the options available if adverse effects occur.
Effective shared decision-making may include:
- Connecting the medication to the patient’s prior cardiovascular event.
- Explaining expected benefit in understandable terms.
- Asking about the patient’s goals and concerns.
- Discussing treatment alternatives if the initial regimen is not tolerated.
- Agreeing on a monitoring and follow-up plan.
- Reinforcing that treatment decisions can be revisited rather than stopping therapy without an alternative plan.
How Pharmacists and Prescribers Can Work Together
Pharmacists can partner with prescribers to identify medication gaps, optimize statin therapy, and help patients remain on treatment. Pharmacists can support the statin space by:
- Identifying patients with ASCVD who do not have a current statin prescription or fill and notifying the prescriber of the potential care gap
- Reviewing the medication list, statin intensity, refill history, and adherence patterns to identify opportunities for initiation or optimization
- Educating patients about how statins reduce the risk of another heart attack or stroke and addressing questions or misconceptions
- Contacting patients with refill gaps, helping synchronize medications, arranging refill reminders, and supporting extended day (i.e. 100-day) supplies when clinically appropriate and covered
- Exploring affordability, transportation, prior authorization, formulary, and other medication-access barriers
- Assessing reported muscle symptoms, timing, severity, potential interactions, and other contributing factors before therapy is discontinued
- Recommending prescriber review of a lower dose, different statin, alternative dosing schedule, or maximally tolerated regimen when clinically appropriate
- Reinforcing follow-up and clinically indicated laboratory monitoring; routine creatine kinase or liver-enzyme testing is not required for every stable patient, but baseline or symptom-directed testing may be appropriate
- Sharing specific, actionable recommendations with the prescriber and documenting the agreed-upon follow-up plan
Health plan gap reports can further support this collaboration by identifying patients who may not be receiving statin therapy or whose prescription claims suggest possible discontinuation. Claims information should prompt medication reconciliation and patient outreach rather than be treated as definitive evidence that a patient is not taking therapy.
Practical Prescribing Pearls
- Focus on cardiovascular protection. Explain that the purpose of statin therapy is to reduce the risk of another heart attack, stroke, or vascular procedure.
- Use high-intensity therapy when appropriate and tolerated.
- Do not assume a prescription equals adherence. Review refill history and ask directly about missed doses.
- Investigate symptoms before labeling a patient statin intolerant.
- Rechallenge when clinically appropriate. A different statin or lower daily dose may be tolerated. An intermittent schedule may be considered for selected patients who cannot tolerate daily dosing, but it should not be presented as equivalent to a standard daily high-intensity regimen.
- Use maximally tolerated therapy. Partial statin tolerance can still provide meaningful LDL-C lowering.
- Reassess the treatment plan after transitions of care. Hospital discharge, rehabilitation, and post-event follow-up are important opportunities to prevent unintentional discontinuation.
- Engage pharmacy early. Pharmacists can assist with adherence, education, access barriers, potential interactions, and follow-up.
References
- Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87(19):2624-2757. doi:10.1016/j.jacc.2025.11.016. Published online March 13, 2026. Correction published September 8, 2026. doi:10.1161/CIR.0000000000001475.
- Palaniappan LP, Allen NB, Almarzooq ZI, et al; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee. Heart Disease and Stroke Statistics—2026 Update: A Report of US and Global Data From the American Heart Association. Circulation. 2026;153(9):e275-e906. doi:10.1161/CIR.0000000000001412. Correction published August 4, 2026. doi:10.1161/CIR.0000000000001469.
- Centers for Disease Control and Prevention. Heart Disease Facts. Updated October 24, 2024. Accessed October 8, 2026.
- Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119. doi:10.1161/CIR.0000000000001168.
- Cheeley MK, Saseen JJ, Agarwala A, et al. NLA Scientific Statement on Statin Intolerance: A New Definition and Key Considerations for ASCVD Risk Reduction in the Statin Intolerant Patient. J Clin Lipidol. 2022;16(4):361-375. doi:10.1016/j.jacl.2022.05.068.
- American College of Cardiology. Statin Intolerance Tool. Lipid Manager. Accessed October 8, 2026.
SPC: Statin Therapy for Patients with Cardiovascular Disease
Product Line: Medicaid, Medicare, Marketplace
Statin Therapy for Patients with Cardiovascular Disease (SPC) is a HEDIS measure that focuses on patients and their adherence to at least one high or moderate-intensity statin medication therapy during the measurement year.
Service Needed
Male patients 21-75 years of age and female patients 40-75 years of age, with a diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD) and being treated with and remain taking a high or moderate-intensity statin medication.
Two rates reported for this measure are:
- The percentage of patients who are dispensed at least one high or moderate-intensity statin medication during the measurement year.
- Percentage of patients who remain on a high or moderate-intensity statin medication for at least 80 percent of the treatment period.
Tips for Attainment:
- At each visit, review the medication list and ask if there are any issues with filling or taking medications as prescribed. If there are any problems/issues with the medication, open-ended questions will assist you with solutions and remove patient barriers to adherence.
- Educate members on the purpose of the medication, including how often to take the medication and possible side effects. Advise member to contact provider's office if side effects occur or are suspected.
- Assess health literacy to determine need for additional support in medication management.
- Offer a 100-day supply of medication to members, if stable.
- Encourage member to sign up with their retail or mail-order pharmacy.
- Reminder calls, emails, text messages or mailings can assist with ensuring members do not miss scheduled appointments.
- Schedule an annual visit or follow-up visit before the member leaves the office.
- Ensure member completes any required labs such as cholesterol, kidney values (both blood and urine) and/or A1c
Buckeye Initiatives:
Weekly Outreach
- Data analytics team generates weekly report identifying BHP members with diagnosis of ASCVD and no record of statin therapy
- Pharmacy team makes up to 2 fax attempts to each provider for each identified member to request provider to evaluate if statin therapy is appropriate for member
- No response from fax outreach, then Buckeye clinical pharmacist (when appropriate) attempts to contact provider to review and resolve the opportunity.
- For members currently taking statin therapy but fall below 80% adherence – fax outreach is made to provider to alert them that member is non-adherent to their statin therapy. Cardiovascular disease (CVD) is the leading cause of morbidity and death in the US, resulting in more than 1 of every 4 deaths.1 Coronary heart disease is the single leading cause of death and accounts for 43% of deaths attributable to CVD in the US.
In 2019, an estimated 558 000 deaths were caused by coronary heart disease and 109 000 deaths were caused by ischemic stroke. Men have a higher overall prevalence of and mortality from CVD, although women experience higher mortality from certain cardiovascular events, such as stroke. On average, men experience CVD events earlier in life compared with women. The prevalence of CVD also differs by race and ethnicity. Among both sexes, Black adults have the highest prevalence of CVD.
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults
2024 Heart Disease and Stroke Statistics Update Fact Sheet (PDF)
For more information and improvement tips see the SPC page of our HEDIS Reference Guide (PDF).
SPD: Statin Therapy for Patients with Diabetes (SUPD below)
Product Line: Medicaid, Medicare, Marketplace
Statin Therapy for Patients with Diabetes is a HEDIS measure that focuses on patients and their adherence to at least one statin medication of any intensity during the measurement year.
Service Needed
Patients 40 to 75 years of age with diagnosis of diabetes who do not have diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD) and being treated with and remain taking at least one statin medication of any intensity.
Two rates reported for this measure are:
- The percentage of patients who are dispensed at least one statin medication of any intensity during the measurement year.
- Percentage of patients who remain on a statin medication of any intensity for at least 80 percent of the treatment period.
Tips for Attainment:
- At each visit, review the medication list and ask if there are any issues with filling or taking medications as prescribed. If there are any problems/issues with the medication, open-ended questions will assist you with solutions and remove patient barriers to adherence.
- Assess health literacy to determine need for additional support in medication management.
- Educate members on the purpose of taking a statin medication to prevent cardiovascular disease. Discuss how often to take the medication and possible side effects.
- Advise member to contact provider's office if side effects occur or are suspected. Consider an alternative dosing schedule to prevent or lessen side effects.
- Offer 100-day supply of medication to members, if stable.
- Encourage member to sign up for mail orders at their retail or mail-order pharmacy.
- Reminder calls, emails, text messages or mailings can assist with ensuring members do not miss scheduled appointments.
- Schedule an annual visit or follow-up visit before the member leaves the office.
- Ensure member completes any required labs such as cholesterol, kidney values (both blood and urine) and/or A1c.
SUPD: Statin Use in Persons with Diabetes
Product Line: Medicare
Statin Use in Persons with Diabetes is a Medicare measure that is defined as the percent of Medicare Part D beneficiaries ages 40 to 75 who were dispensed at least two diabetes medication fills on unique days of service and received a statin medication fill during the measurement period.
Service Needed
Patients 40 to 75 years of age with diagnosis of diabetes being treated with and remain taking at least one statin medication of any intensity.
The rate reported for this measure is:
The percentage of Medicare Part D beneficiaries ages 40 to 75 who were dispensed at least two diabetes medication fills on unique days of service and received a statin medication fill during the measurement period.
Tips for Attainment:
- At each visit, review the medication list and ask if there are any issues with filling or taking medications as prescribed. If there are any problems/issues with the medication, open-ended questions will assist you with solutions and remove patient barriers to adherence.
- Assess health literacy to determine need for additional support in medication management.
- Educate members on the purpose of taking a statin medication to prevent cardiovascular disease. Discuss how often to take the medication and possible side effects.
- Advise member to contact provider's office if side effects occur or are suspected. Consider an alternative dosing schedule to prevent or lessen side effects.
- Offer 100-day supply of medication to members, if stable.
- Encourage member to sign up for mail orders at their retail or mail-order pharmacy.
- Reminder calls, emails, text messages or mailings can assist with ensuring members do not miss scheduled appointments.
- Schedule an annual visit or follow-up visit before the member leaves the office.
- Ensure member completes any required labs such as cholesterol, kidney values (both blood and urine) and/or A1c.
- Diabetes is an epidemic in the United States. According to the Centers for Disease Control and Prevention (CDC), over 38 million Americans have diabetes and face its devastating consequences. What’s true nationwide is also true in Ohio. Obesity is linked to up to 53 percent of new cases of type 2 diabetes each year. Treating the chronic disease of obesity can help prevent, delay, and even result in diabetes remission. See the great information provided by the AMA below.
AMA - The Burden of Diabetes in OhioExternal Link
For more information, exclusions and improvement tips see our HEDIS Reference Guide (PDF).
Pharmacist Provider Status
Pharmacist Provider Status in Ohio: A Collaborative Step Toward Better Patient Care
The healthcare landscape is evolving, and Ohio is at the forefront of a movement that recognizes pharmacists as essential providers of clinical care. With the passage of Senate Bill 265 in 2019, Ohio formally granted provider status to pharmacists, enabling them to bill Medicaid for clinical services and integrate more fully into patient care teams.
This advancement is not just a win for pharmacy—it’s a win for interdisciplinary care, patient access, and health system efficiency.
What Is Pharmacist Provider Status?
Pharmacist provider status allows licensed pharmacists to be recognized as healthcare providers under state law, enabling reimbursement for clinical services such as:
- Medication therapy management (MTM)
- Chronic disease management
- Preventive care and immunizations
- Point-of-care testing
- Telehealth consultations
Under Ohio Medicaid, pharmacists can bill for specific pharmacist billable services using CPT codes, as other providers would.
Legislative and Regulatory Framework
- Senate Bill 265 (2019): Signed by Governor John Kasich, this bill redefined pharmacists as healthcare providers under Ohio law.
- Ohio Administrative Code Rule 5160-8-52: Outlines the scope of reimbursable services, including medication management, immunizations, and telehealth.
- Medicaid Managed Care Integration: Pharmacists must contract with Managed Care Organizations (MCOs) to bill for services. As of 2021, Ohio transitioned to a universal credentialing platform to streamline this process.
Clinical and Economic Impact
1. Improved Patient Outcomes
A study evaluating pharmacist-led services in Ohio Medicaid programs found that pharmacists were most frequently reimbursed for office visits, and their interventions led to improved medication adherence and chronic disease management.
In oncology settings, pharmacist-led interventions had an 82% acceptance rate and significantly improved therapy management, including dose adjustments and drug interaction mitigation.
Additionally, for Buckeye specifically, pharmacists as providers have been able to impact outcomes for members across several HEDIS measures. Pharmacists have been able to contribute to the following improvements for members with clinical interventions:
- Members were 66% more likely to have high blood pressure control
- Members were five times more likely to get an A1c screening
- Members were 88% more likely to have better A1c control
- Members with diabetes were twice as likely to have statin therapy added to their medication regimen
- Members with cardiovascular disease were three times as likely to have statin therapy added to their medication regimen
2. Reduced Healthcare Utilization
Pharmacist-led medication therapy management (MTM) programs have demonstrated:
- Fewer hospital readmissions due to medication-related issues
- Enhanced adherence in chronic conditions like diabetes and hypertension
- Positive return on investment for employers and payors
3. Expanded Access to Care
Pharmacists are often the most accessible healthcare professionals. In rural and underserved areas, their ability to provide clinical services helps bridge gaps in care, especially for patients with limited access to primary care providers.
What This Means for Healthcare Professionals
Pharmacist provider status is not about expanding pharmacy in isolation—it’s about enhancing team-based care. Here’s how it benefits other professionals:
- Physicians: Gain collaborative support in managing complex medication regimens and chronic conditions.
- Nurses: Benefit from pharmacist-led education and adherence strategies that reduce medication errors.
- Administrators: See improved quality metrics and reduced costs through pharmacist-led interventions.
- Allied Health Providers: Collaborate more effectively with pharmacists in holistic patient care plans.
Looking Ahead
While Ohio has made significant strides, federal recognition of pharmacists as providers under Medicare remains a key goal. Continued advocacy is essential to expand reimbursement and fully integrate pharmacists into national healthcare models.
Conclusion
Pharmacist provider status in Ohio is more than a policy change—it’s a paradigm shift. By recognizing pharmacists as clinical providers, Ohio is fostering a more collaborative, efficient, and patient-centered healthcare system. For all healthcare professionals, this is an opportunity to embrace a model where every member of the care team contributes to better outcomes.
Polypharmacy
The Polypharmacy – Anticholinergic Medications (Poly-ACH) measure, which is part of the 2026 Medicare Star Ratings program, focuses on the concurrent use of multiple unique anticholinergic medications in adults, aged 65 and older. While there are instances where it may be appropriate for different anticholinergic medications to be prescribed together, the concurrent use of multiple anticholinergics in older adults is associated with an increased risk of cognitive decline based on the American Geriatrics Society Beers Criteria. Other adverse reactions from concurrent use include blurred vision, constipation, dry mouth, and urinary retention.
- Approximately 6% of older adult physician visits result in a prescription for a high-risk anticholinergic [1]
- Anticholinergic medication use is associated with adverse clinical outcomes, especially in older adults. The heightened susceptibility of older adults to the effects of anticholinergic medications is influenced by age-related changes in the nervous system, as well as alterations in pharmacokinetics and pharmacodynamics [2]
- Hospitalized older patients with a high anticholinergic burden at discharge (ACB ≥ 3) have a nearly 3-fold higher hazard ratio [2]
- Key points for the Poly-ACH measure include:
- Members qualify for the measure if they are 65 years of age or older and have at least two prescription claims of the same anticholinergic medication with different dates of service
- Members are non-compliant by having at least two prescription claims of 2 or more unique anticholinergic medications with different dates of service with concurrent use for at least 30 cumulative days
- Once a member surpasses 30 days of overlap with 2 or more unique anticholinergic medications, they can no longer become compliant during the measurement year
- Exclusions include any member with hospice enrollment
We recommend a review of these anticholinergic medications and discontinuation of one of the medications, if possible. Another potential option is to switch one of the medications to a safer alternative (please refer to table below for examples of safer alternatives). If concurrent use is unavoidable, we recommend continuing at the lowest effective doses along with the shortest duration possible. Other considerations when your patient is taking multiple anticholinergic medications together include:
- Monitor patients closely for signs of adverse reactions
- Educate your patient about the risks of combining different anticholinergic medications which may include increased risk of confusion and falls
- Discuss with your patient about the opportunity of switching to a potentially equally effective safer alternative medication
[1] Journal of the American Geriatrics Society, National Prescribing Trends for High-Risk Anticholinergic Medications in Older Adults, July 2018.
[2] Public Library of Science (PLOS) ONE, Anticholinergic burden and clinical outcomes among older adults admitted in a tertiary hospital: a prospective cohort study, September 2025.
Commonly Prescribed Anticholinergic Medications | Potentially Safer Alternative(s) |
amitriptyline | For depression: escitalopram, sertraline, bupropion; For sleep: trazodone, melatonin; For pain: acetaminophen, duloxetine, lidocaine topical, capsaicin topical |
benztropine | For extrapyramidal symptoms: adjust dose or switch to a different antipsychotic, amantadine; For Parkinson's: carbidopa/levodopa, ropinirole, pramipexole |
cyclobenzaprine | baclofen, tizanidine, acetaminophen, physical therapy |
dicyclomine | loperamide, cholestyramine, eluxadoline (Viberzi) |
diphenhydramine | cetirizine, fexofenadine, loratadine, desloratadine, levocetirizine, steroid nasal sprays |
hydroxyzine | cetirizine, fexofenadine, loratadine, desloratadine, levocetirizine; For anxiety: escitalopram, sertraline, buspirone; For sleep: trazodone, melatonin |
meclizine | Identify and address underlying cause(s) of dizziness |
olanzapine | risperidone, aripiprazole, ziprasidone |
oxybutynin | mirabegron (Myrbetriq), vibegron (Gemtesa) |
paroxetine | escitalopram, sertraline |
prochlorperazine | ondansetron |
trospium | mirabegron (Myrbetriq), vibegron (Gemtesa) |
*Not all-inclusive list and does not guarantee coverage
Pharmacy Quality in the Community
By Tiffany Haddad-Azzi, PharmD, RPh
Community pharmacists play a critical role in improving medication safety for older adults and helping Medicare beneficiaries avoid preventable medication-related harm. Two important Medicare Part D Star measures focus on identifying potentially unsafe medication combinations that can increase the risk of falls, fractures, overdose, hospitalization, cognitive impairment, and mortality in older adults. These measures are:
- Concurrent Use of Opioids and Benzodiazepines (COB)
- Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults (Poly-ACH)
Because pharmacists have direct access to medication histories and frequent patient interactions, they are uniquely positioned to identify opportunities for deprescribing, recommend safer therapeutic alternatives, and educate both patients and prescribers.
Concurrent Use of Opioids and Benzodiazepines (COB)
Measure Definition
The COB measure evaluates the percentage of Medicare beneficiaries aged 18 years and older who receive concurrent opioid and benzodiazepine therapy for 30 cumulative days or more during the measurement year.
The combination of opioids and benzodiazepines significantly increases the risk of:
- Respiratory depression
- Excessive sedation
- Falls and fractures
- Cognitive impairment
- Accidental overdose and death
How Pharmacists Can Impact the Measure
Community pharmacists often identify these combinations before anyone else. Key opportunities include:
- Reviewing medication profiles for overlapping opioid and benzodiazepine prescriptions
- Contacting prescribers when long-term combination therapy is identified
- Assessing whether both medications remain clinically necessary
- Providing naloxone education and access when appropriate
- Counseling patients about sedation, impaired driving, and overdose risk
- Encouraging use of the lowest effective dose and shortest duration possible when concurrent therapy cannot be avoided
Pharmacist intervention can help reduce unnecessary exposure while improving patient safety and Star measure performance. Improvement strategies identified in pharmacy quality resources include reviewing opioid and benzodiazepine therapy, discontinuing one or both agents when clinically appropriate, using gradual tapers rather than abrupt discontinuation, monitoring for misuse and adverse effects, and providing patient education regarding risks.
Deprescribing Tips for COB
Before recommending discontinuation:
- Assess the original indication and current benefit.
- Determine whether nonpharmacologic therapies may be appropriate.
- Coordinate with all treating providers.
- Avoid abrupt discontinuation.
Potential alternatives may include:
- Cognitive behavioral therapy for anxiety or insomnia
- SSRIs or SNRIs when clinically appropriate
- Non-opioid pain management strategies
- Physical therapy and functional restoration programs
- Topical analgesics for localized pain
Key Note: ensure that alternatives recommended are not anticholinergic medications that would pose risk of a member becoming noncompliant in Poly-ACH
Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults (Poly-ACH)
Measure Definition
The Poly-ACH measure evaluates Medicare beneficiaries aged 65 years and older who receive two or more unique anticholinergic medications. Anticholinergic burden is associated with substantial safety risks in older adults. According to materials used in Buckeye’s outreach program, beneficiaries are identified based on use of multiple distinct anticholinergic medications over time.
Why It Matters
Anticholinergic medications can cause:
- Confusion and delirium
- Memory impairment
- Dizziness
- Falls and fractures
- Constipation
- Urinary retention
- Increased hospitalization risk
Older adults are particularly vulnerable because age-related physiologic changes make it more difficult to tolerate cumulative anticholinergic effects.
How Pharmacists Can Impact the Measure
Pharmacists should routinely screen older adults for anticholinergic burden, especially those taking medications from multiple prescribers.
Recommended actions include:
- Reviewing the complete medication profile for duplicate or additive anticholinergic therapy
- Identifying medications that may no longer be clinically necessary
- Recommending safer alternatives when available
- Educating patients regarding cognitive and fall risks
- Monitoring for adverse effects and functional decline
Pharmacy quality guidance recommends reviewing therapy, deprescribing when appropriate, transitioning members to safer alternatives, and monitoring for adverse reactions.
Deprescribing Opportunities
Medication Class | Common Anticholinergic Examples | Potential Alternatives |
First-generation antihistamines | Diphenhydramine, chlorpheniramine | Cetirizine, loratadine, fexofenadine |
Overactive bladder agents | Oxybutynin, tolterodine | Behavioral therapy, mirabegron where appropriate |
Tricyclic antidepressants | Amitriptyline, doxepin | SSRIs or SNRIs when appropriate (excluding paroxetine) |
Skeletal muscle relaxants | Cyclobenzaprine | Non-pharmacologic pain management, baclofen, tizanidine |
Certain antipsychotics and antiemetics | Varies | Individualized alternatives based on indication |
Practical Deprescribing Principles
For both COB and Poly-ACH, successful deprescribing often involves:
- Shared decision-making with patients and caregivers
- Gradual tapering when discontinuation is appropriate
- Collaboration with prescribers
- Monitoring withdrawal symptoms or recurrence of underlying conditions
- Considering patient goals, functional status, and quality of life
Community Pharmacy Action Steps
When reviewing Medicare patients, pharmacists should ask:
✓ Is this medication still needed?
✓ Is the benefit greater than the risk?
✓ Are there safer alternatives available?
✓ Is the patient experiencing side effects that may not have been recognized?
✓ Can medication burden be reduced without compromising outcomes?
Even brief pharmacist interventions can prevent medication-related harm and improve quality outcomes.
The Bottom Line
The Medicare COB and Poly-ACH measures are more than quality metrics. They identify medication-related risks that can significantly affect the health, safety, and independence of older adults. Community pharmacists remain one of the most effective safeguards against inappropriate medication use through medication therapy management, proactive prescriber collaboration, patient counseling, and thoughtful deprescribing efforts. By identifying high-risk medication combinations and promoting safer alternatives, pharmacists can improve both Star measure performance and patient outcomes across Ohio. |